---
title: "Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission"
description: "Adia Nutrition Inc. has submitted its Form 10 registration statement to the SEC, marking a significant transition from OTC reporting to full SEC compliance. This move enhances the company's transparen"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261075948.md"
published_at: "2025-10-14T13:00:21.000Z"
---

# Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission

> Adia Nutrition Inc. has submitted its Form 10 registration statement to the SEC, marking a significant transition from OTC reporting to full SEC compliance. This move enhances the company's transparency and credibility, positioning it for a Nasdaq listing and attracting institutional investors. The filing is expected to be submitted by November 2025, with full effectiveness anticipated by January 2026. CEO Larry Powalisz emphasized that this milestone will open doors to strategic growth opportunities in regenerative medicine and advanced biologics.

Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing marks a significant step beyond OTC reporting and positions Adia as a fully reporting public company under the Securities Exchange Act of 1934, a critical move that enhances transparency, credibility, and access to the broader capital markets. Unlike OTC reporting, which provides limited disclosure, full SEC reporting requires comprehensive audited financials, regular operational updates, and robust corporate governance, all of which unlock new opportunities for growth and investment.

Adia expects to submit the Form 10 by the end of November 2025, with the SEC review and recognition period set at 60 days. Based on this timeline, the filing is anticipated to become fully effective by late January 2026. This advancement is also a key step toward meeting Nasdaq listing requirements, bringing Adia closer to joining one of the world's most prestigious stock exchanges and attracting a new class of institutional and accredited investors.

"Filing the Form 10 is a transformative moment for Adia Nutrition," said Larry Powalisz, CEO of Adia Nutrition Inc. "Transitioning from OTC reporting to full SEC compliance elevates our visibility and credibility, opens doors to sophisticated investors, and sets the stage for strategic growth opportunities as we continue expanding our leadership in regenerative medicine, advanced biologics, and clinical services nationwide."

With full SEC reporting status, Adia expects to attract institutional investors, mutual funds, and accredited investors who typically only invest in fully reporting companies. The increased transparency and regulatory compliance will also enable strategic partnerships and broader market recognition, fueling the next stage of Adia's rapid expansion. The Company's accounting and legal teams are finalizing documentation and audits to ensure a smooth submission, and shareholders can expect regular updates as the filing and SEC recognition process progresses.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

**About ADIA Nutrition Inc.:**

Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com

Website: www.adiamed.com

Website: www.adialabs.com

Website: www.biolete.com

Website: www.cementfactory.co

Twitter (X): @ADIA\_Nutrition

**Safe Harbor:** This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270232

### Related Stocks

- [NDAQ.US - Nasdaq](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Baader Bank Aktiengesellschaft Sells 54,069 Shares of Nasdaq, Inc. $NDAQ | Baader Bank Aktiengesellschaft reduced its stake in Nasdaq, Inc. by 86.5% in Q3, selling 54,069 shares, leaving it with  | [Link](https://longbridge.com/en/news/275735016.md) |
| Fifth Third Bancorp Insider Sold Shares Worth $5,203,267, According to a Recent SEC Filing | 03:08 PM EST, 02/13/2026 (MT Newswires) -- Mitchell Stuart Feiger, Director, on February 11, 2026, sold 97,516 shares in | [Link](https://longbridge.com/en/news/275941629.md) |
| Caterpillar Insider Sold Shares Worth $1,312,623, According to a Recent SEC Filing | 03:21 PM EST, 02/13/2026 (MT Newswires) -- Jason Kaiser, Group President, on February 12, 2026, sold 1,690 shares in Cat | [Link](https://longbridge.com/en/news/275942492.md) |
| Polaris Insider Sold Shares Worth $2,344,696, According to a Recent SEC Filing | 04:30 AM EST, 02/13/2026 (MT Newswires) -- Michael T Speetzen, Chief Executive Officer, on February 10, 2026, sold 35,08 | [Link](https://longbridge.com/en/news/275882058.md) |
| Polaris Insider Sold Shares Worth $520,335, According to a Recent SEC Filing | 04:29 AM EST, 02/13/2026 (MT Newswires) -- Robert Paul Mack, Chief Financial Officer, Executive Vice President of Financ | [Link](https://longbridge.com/en/news/275881976.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
